Hours

Minutes

Seconds

-40%

on all subscriptions*

Last hours

Enjoy this offer

* See conditions under "Our services"

ABION Inc. is a Korea-based company principally engaged in the research, development and sales of pharmaceuticals. Along with its subsidiaries, the Company operates its business through four segments including product segment, contract research organization (CRO) service segment, research segment and other segment. The Product segment produces and sells diagnostic reagents, research reagents, and stem cell culture medium. The CRO Service segment provides histopathology analysis, molecular genetic analysis, cellular immunoassay, and antibody detection services. The Research segment is engaged in research and development of drugs for protein therapeutics, nucleic acid therapeutics, and antibody therapeutics.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-06-18	1,172.00 ₩	-8.94%	1,097,872
26-06-17	1,287.00 ₩	+1.50%	645,142
26-06-16	1,268.00 ₩	+0.63%	623,705
26-06-15	1,260.00 ₩	+2.86%	897,278
26-06-12	1,225.00 ₩	-0.65%	1,310,176

End-of-day quote Korea S.E.

More quotes

Income Statement and Estimates

More financial data

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

End-of-day quote Korea S.E. Other stock markets 2026-06-18			5-day change	1st Jan Change
1,172.00 ^KRW	-8.94%		-4.95%	-62.56%

04-07	ABION Announces Preclinical Data Showing IFN-? Antibody Fusion Abn202 Outperforms Trop2-Targeting ADCs	CI
25-04-04	Abion To Divest 5.9 Billion Won Worth Of Shares In Vivozon Inc	RE

Market Cap	106B 68.73M 59.89M 55.2M 51.93M 97.14M 6.48B 97.83M 657M 255M 3.19B 258M 252M 11.06B	P/E 2024	-4.02x	P/E 2025	-7.21x
Enterprise Value	77.26B 50.29M 43.82M 40.39M 37.99M 71.08M 4.74B 71.58M 481M 187M 2.34B 189M 185M 8.1B	EV / Sales 2024	282x	EV / Sales 2025	288x
Free-Float	67.22%	Yield 2024 *	-	Yield 2025	-

04-07	ABION Announces Preclinical Data Showing IFN-? Antibody Fusion Abn202 Outperforms Trop2-Targeting ADCs	CI
25-04-04	Abion To Divest 5.9 Billion Won Worth Of Shares In Vivozon Inc	RE
24-12-29	Nuon Co., Ltd. completed the acquisition of 4.06% stake in ABION Inc. from KPM TECH Co., Ltd..	CI
24-12-25	KPM TECH Co., Ltd. announced that it has received KRW 5.999999711 billion in funding from ABION Inc.	CI
24-12-22	Nuon Co., Ltd. agreed to acquire 4.06% stake in ABION Inc. from KPM TECH Co., Ltd. for KRW 8 billion.	CI
24-12-22	ABION Inc. announced that it has received KRW 8.0011152 billion in funding from TELCON RF PHARMACEUTICAL. Inc.	CI
24-12-17	KPM TECH Co., Ltd. announced that it expects to receive KRW 5.999999711 billion in funding from ABION Inc.	CI
24-12-04	ABION Inc. completed the acquisition of 7.56% stake in Vivozon, Inc. from TELCON RF PHARMACEUTICAL. Inc..	CI
24-12-04	ABION Inc. announced that it has received KRW 20.019993378 billion in funding from TELCON RF PHARMACEUTICAL. Inc.	CI
24-11-10	ABION Inc. announced that it expects to receive KRW 20.019993378 billion in funding from TELCON RF PHARMACEUTICAL. Inc.	CI
24-11-10	ABION Inc. agreed to acquire 7.56% stake in Vivozon, Inc. from TELCON RF PHARMACEUTICAL. Inc. for KRW 20.1 billion.	CI
24-10-27	ABION Inc. announced that it expects to receive KRW 9.999995616 billion in funding from TELCON RF PHARMACEUTICAL. Inc.	CI
23-12-27	Abion Inc. announced that it has received KRW 7.999997049 billion in funding from TELCON RF PHARMACEUTICAL. Inc., Gencurix Inc.	CI

1 day	-8.94%
1 week	-4.95%
Current month	-37.76%
1 month	-41.69%
3 months	-59.38%
6 months	-59.02%
Current year	-62.56%

Abion Inc. Stock

Stocks

A203400

KR7203400007

Biotechnology & Medical Research

Valuation: Abion Inc.

Chart: Abion Inc.

Latest news : Abion Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Abion Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

1 week	1,169	1,351
1 month	1,066	2,400
Current year	1,066	4,335
1 year	1,066	7,277.78
3 years	1,066	7,277.78
5 years	1,066	14,694.44
10 years	1,066	14,694.44

Manager	Title	Age	Since
Young-Gi Shin CEO	Chief Executive Officer	55	2010-07-31
Seong-Yun Woo DFI	Director of Finance/CFO	45	2025-03-27
Gi-Ryong Jang COO	Chief Operating Officer	46	2025-12-31

Director	Title	Age	Since
Young-Gi Shin BRD	Director/Board Member	55	2014-12-30
Jin-Wook Yang BRD	Director/Board Member	56	2022-03-24
Geun-Chul Park BRD	Director/Board Member	70	-

Date	Insider	Type	Quantity	% Market Cap.
12-07	Sun-mi Chang	Buy	34	0.0001%
12-07	Yang-mi Lim	Free	92	0.0002%
12-07	Yang-mi Lim	Buy	115	0.0002%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ABION INC.	-8.94%	-4.95%	-55.91%	-72.71%	68.73M
ARGENX SE	+1.13%	-1.63%	+62.89%	+114.05%	54.44B
WUXI APPTEC CO., LTD.	+4.60%	+5.82%	+56.35%	+43.04%	45.8B
BIONTECH SE	-1.44%	+1.51%	-12.94%	-19.24%	22.98B
INSMED INCORPORATED	-2.69%	-0.95%	-3.68%	+379.00%	20.76B
WUXI BIOLOGICS (CAYMAN) INC.	+3.22%	+2.94%	+24.02%	-35.05%	16.25B
GENMAB A/S	+1.28%	+2.01%	+17.80%	-37.49%	15.34B
EXELIXIS, INC.	-1.01%	-2.97%	+27.42%	+171.92%	13.05B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+3.07%	+5.43%	+21.37%	-	12.37B
PHARMAESSENTIA CORPORATION	+4.95%	+13.49%	+121.11%	+249.05%	12.47B
Average	+0.41%	+1.53%	+25.84%	+88.06%	21.35B
Weighted average by Cap.	+1.58%	+1.38%	+39.44%	+98.46%

	2024	2025
Net sales	760M 494K 431K 397K 374K 699K 46.6M 704K 4.72M 1.83M 22.97M 1.86M 1.82M 79.6M	880M 573K 499K 460K 433K 810K 53.99M 815K 5.47M 2.13M 26.61M 2.15M 2.1M 92.22M
Net income	-43.38B -28.24M -24.6M -22.68M -21.33M -39.91M -2.66B -40.19M -270M -105M -1.31B -106M -104M -4.55B	-29.06B -18.92M -16.48M -15.19M -14.29M -26.74M -1.78B -26.92M -181M -70.2M -879M -71M -69.48M -3.05B
Net Debt	14.05B 9.14M 7.97M 7.34M 6.91M 12.92M 862M 13.01M 87.37M 33.93M 425M 34.32M 33.58M 1.47B	-28.33B -18.44M -16.07M -14.81M -13.93M -26.06M -1.74B -26.25M -176M -68.44M -857M -69.22M -67.74M -2.97B